As Biotechnology companies, Homology Medicines Inc. (NASDAQ:FIXX) and VBI Vaccines Inc. (NASDAQ:VBIV) are our subject to compare. And more specifically their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Homology Medicines Inc.||3.68M||249.80||57.22M||-2.50||0.00|
|VBI Vaccines Inc.||3.35M||55.60||63.60M||-0.90||0.00|
Table 1 demonstrates Homology Medicines Inc. and VBI Vaccines Inc.’s top-line revenue, earnings per share and valuation.
Table 2 provides us Homology Medicines Inc. and VBI Vaccines Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Homology Medicines Inc.||-1,554.89%||0%||0%|
|VBI Vaccines Inc.||-1,898.51%||0%||0%|
The Ratings and Recommendations for Homology Medicines Inc. and VBI Vaccines Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Homology Medicines Inc.||0||0||1||3.00|
|VBI Vaccines Inc.||0||0||0||0.00|
Homology Medicines Inc.’s upside potential currently stands at 68.07% and an $36 consensus target price. Meanwhile, VBI Vaccines Inc.’s consensus target price is $9, while its potential upside is 371.20%. The results provided earlier shows that VBI Vaccines Inc. appears more favorable than Homology Medicines Inc., based on analyst belief.
Institutional & Insider Ownership
Institutional investors owned 91.6% of Homology Medicines Inc. shares and 55.46% of VBI Vaccines Inc. shares. Insiders owned roughly 10.06% of Homology Medicines Inc.’s shares. Competitively, 11.91% are VBI Vaccines Inc.’s share owned by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Homology Medicines Inc.||6.25%||41.64%||30.09%||80.11%||0%||28.4%|
|VBI Vaccines Inc.||8.29%||17.37%||20.25%||-2.97%||-48.69%||22.5%|
For the past year Homology Medicines Inc. has stronger performance than VBI Vaccines Inc.
Homology Medicines Inc. beats on 8 of the 10 factors VBI Vaccines Inc.
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. The company also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants. In addition, it is developing CMV vaccine program, which is in Phase I clinical trials for the prevention of human cytomegalovirus infection; and for glioblastoma multiforme, which is in preclinical testing stage. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.